Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04004507 · ClinicalTrials.gov registry record · Phase 2
Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances
A Phase 2 study, sponsored by Ocuphire Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT04004507: Completed Phase 2 study, sponsored by Ocuphire Pharma.
NCT04004507 is a Phase 2 study that has completed, run by Ocuphire Pharma. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04004507, a Phase 2 study, has completed, sponsored by Ocuphire Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objectives of this study are: * To assess the effect of ophthalmic phentolamine mesylate in mesopic conditions on the four endpoints: 1. Contrast sensitivity 2. Low contrast visual acuity 3. Wavefront aberrometry 4. Subjective questionnaire * To assess the safety of ophthalmic phentolamine mesylate
Primary Outcome
Average change in monocular contrast sensitivity scores under mesopic conditions at each of five spatial frequencies with and without glare. The tests were performed in a darkened room using the Optec 6500 instrument (Stereo Optical) using Slides 5-9 (spatial frequencies 1.5 - 18 cycles per degree), with the distance setting at "far", and with the light setting at "night". Subjects were asked to read each slide from left to right indicating if the lines were tilted to the left, the right or str
Interventions
- OTHER Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
- DRUG Phentolamine Mesylate Ophthalmic Solution 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
What the finished NCT04004507 record still lists
NCT04004507 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) is the first listed.
NCT04004507 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04004507 about?
NCT04004507 is a clinical study titled "Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances". The objectives of this study are: * To assess the effect of ophthalmic phentolamine mesylate in mesopic conditions on the four endpoints: 1. Contrast sensitivity 2. Low contrast visual acuity 3. Wavefront aberrometry 4. Subjective questionnaire * To assess the safety of ophthalmic phentola...
What is the current status of trial NCT04004507?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2007-08. Estimated completion is 2008-02.
What interventions are being tested in trial NCT04004507?
The interventions under investigation include: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) (OTHER), Phentolamine Mesylate Ophthalmic Solution 1% (DRUG).
Who is sponsoring clinical trial NCT04004507?
This trial is sponsored by Ocuphire Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04004507's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia